White House Budget includes Prescription Drug Cost Provisions and Publish NPI Numbers on Open Payments

Recently, the White House released its 2017 Budget through the Office of Management and Budget (OMB). In the Budget, the Administration lays out some of its concerns about our current healthcare system, including drug costs as they relate to Medicare, Medicaid, and transparency. Addressing the High Cost of Drugs The cost of drugs continues to take center stage, with constant Congressional hearings and Congressional inquiries and probes. The saga now moves to the Executive Branch of the government, with this budget including a package of proposals that focus on Medicare, Medicaid, and drug price transparency. Improving Quality and Lowering Drug Costs for the Medicare Program The White House Budget includes proposals that are expected to lower drug costs, while at the same time increasing transparency and evidence development in the Medicare Part D program. One such proposal is to increase data collection to demonstrate the effectiveness of medications in the Part D program in the Medicare population, and to inform real world clinical treatment. Additionally, the Budget allows the Secretary of Health and Human Services to continue to have the authority to negotiate drug prices for both biologics and more expensive drugs in Medicare Part D. The Budget also includes a new proposal to incentivize Part D plan sponsors to "better manage care provided to beneficiaries with high prescription drug costs." The Budget also proposes to accelerate discounts for brand name drugs...
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs